

COMPLETE ENTIRE FORM AND SUBMIT PEDIGREE/CLINIC NOTES TO AVOID DELAYS

To submit an order via email, please send the completed test requisition form to info@ambrygen.com

COLLECTION DATE (REQUIRED)			
If date of collection is not provided, three calendar days before specimen receipt will be used (for specimens stored longer than 30 days, the day of archive retrieval will be used as the date of service)			
PATIENT INFORMATION			
Legal Name (Last, First, MI)		Date of Birth (MM/DD/YY)	Sex Assigned at Birth ☐ F ☐ M
		Gender (optional) ☐ Man ☐ Woman ☐ Nonbinary ☐ Self-described	
Genetic Ancestry: ☐ Ashkenazi Jewish ☐ Asian ☐ Black/African American ☐ French Canadian/Cajun ☐ Hispanic/Latino ☐ Mediterranean ☐ Middle Eastern ☐ Native American ☐ Pacific Islander ☐ Portuguese ☐ White ☐ Unknown ☐ Other:		MRN	
Address		City	State Zip
Mobile #	Email	Preferred Billing ☐ Insurance ☐ Self-pay ☐ Institutional	
SPECIMEN INFORMATION* (Please see ambrygen.com/specimen-requirements for details)			
☐ Personal history of allogeneic bone marrow or peripheral stem cell transplant		☐ Current diagnosis of heme malignancy, Type:	
Specimen ID:		Medical Record #	
*Fetal specimens, cord blood and POC will have maternal cell contamination studies added for a charge. Maternal and fetal specimen required. Please see page 4 for Maternal Cell Contamination sample submission test codes			
Collection Assistance: ☐ Phlebotomy draw** ☐ Send saliva kit to patient ☐ Send buccal kit to patient ☐ Insurance preverification first (available for ExomeNext® and GenomeNext™) ** As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.			
ORDERING PHYSICIAN/SENDING FACILITY (Each listed person will receive a copy of the report)			
Facility Name (Facility Code)	Address	City	State/Country Zip Phone
Ordering Licensed Provider Name (Last, First)(Code)	NPI#	Phone	Fax Fax/Email
ADDITIONAL RESULTS RECIPIENTS			
Genetic Counselor or Other Medical Provider Name (Last, First) (Code)		Phone/Fax/Email	
CONFIRMATION OF INFORMED CONSENT, PRE-TEST GENETIC COUNSELING, AND MEDICAL NECESSITY FOR GENETIC TESTING I confirm that the genetic test ordered is medically appropriate. All information on this TRF is true to the best of my knowledge. I also confirm that the patient has consented to proceed with genetic testing, including the transfer and processing of their sample and personal/sensitive information in the United States. I agree to allow Ambry Genetics to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider.			
Signature Required for Processing Medical Professional Signature:		Date:	
INSURANCE BILLING (Include copy of both sides of insurance card)		INSTITUTIONAL BILLING	
Patient Relation to Policy Holder? ☐ Self ☐ Spouse ☐ Child	Name and DOB of Policy Holder (if not self)	Facility Name ☐ Send invoice to facility address above	
Insurance Company	Policy #	HMO Auth #	Address
Special Billing Notes:		Contact Name	
		Phone Number	E-mail/Fax
		☐ PATIENT PAYMENT ☐ Check (Payable to Ambry Genetics) ☐ Credit Card (Call 949-900-5795)	
Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetics Corporation (Ambry), authorize Ambry to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending Ambry money received from my health insurance company. ☐ I agree to be contacted regarding future research studies for which I may be a candidate. Any future research projects will be subject to a separate informed consent process and participation is voluntary. Learn more about Ambry's privacy practices at https://www.ambrygen.com/legal/notice-of-privacy-practices . For patient payment by credit card: I hereby authorize Ambry Genetics Corporation to bill my credit card as indicated above.			
For NY Residents: ☐ I understand that New York State law requires Ambry Genetics to destroy my sample at the end of the testing process or not more than sixty days after the sample was taken. By checking this box, I agree that Ambry Genetics will instead retain my sample for at least 6 months after the testing above has been completed, and may (a) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (b) de-identify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law.			
Patient Signature (I agree to terms above):		Date:	

Clinical Genomics Test Requisition Form - Page 2 of 6

ONLY COMPLETE FOR EXOMENEXT® OR GENOMENEXT™ DUO OR TRIO ORDERS OR IF FAMILY MEMBERS WILL BE SUBMITTED FOR CO-SEGREGATION.

All family member specimens must be received within 4 weeks of order. Otherwise test will be run as proband only.

FAMILY MEMBER #1 INFORMATION				
Legal Name (Last, First, MI)		Date of Birth (MM/DD/YY)	Date of Death (If applicable)	Phone Number/Email
Sex Assigned at Birth: ☐ F ☐ M	Gender (optional) ☐ Man ☐ Woman ☐ Nonbinary ☐ Self-described	Genetic Ancestry: ☐ Ashkenazi Jewish ☐ Asian ☐ Black/African American ☐ French Canadian/Cajun ☐ Hispanic/Latino ☐ Mediterranean ☐ Middle Eastern ☐ Native American ☐ Pacific Islander ☐ Portuguese ☐ White ☐ Unknown ☐ Other:		
Address: ☐ Same as Proband		Address	City	State Zip Relationship to proband
SPECIMEN INFORMATION* (Please see ambrygen.com/specimen-requirements for details)				
☐ Personal history of allogenic bone marrow or peripheral stem cell transplant		☐ Current diagnosis of heme malignancy, Type:		
Collection Date	Specimen ID		Medical Record #	
*Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. See ambrygen.com/specimen-requirements for details.				
Collection Assistance: ☐ Phlebotomy draw** ☐ Send saliva kit to patient ☐ Send buccal kit to patient ☐ Insurance preverification first (available for ExomeNext® and GenomeNext™) ** As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.				
CLINICAL INFORMATION				
Does the family member have any features similar to the proband? ☐ Yes ☐ No ☐ Partially ☐ Possibly				
Describe:				
SECONDARY FINDINGS				
Secondary findings results are available for each family member sequenced as part of the trio. Check "decline" to opt-out of the ACMG Recommended List of secondary findings. If left unchecked, secondary findings will be reported for this family member.				
☐ Decline				

FAMILY MEMBER #2 INFORMATION				
Legal Name (Last, First, MI)		Date of Birth (MM/DD/YY)	Date of Death (If applicable)	Phone Number/Email
Sex Assigned at Birth: ☐ F ☐ M	Gender (optional) ☐ Man ☐ Woman ☐ Nonbinary ☐ Self-described	Genetic Ancestry: ☐ Ashkenazi Jewish ☐ Asian ☐ Black/African American ☐ French Canadian/Cajun ☐ Hispanic/Latino ☐ Mediterranean ☐ Middle Eastern ☐ Native American ☐ Pacific Islander ☐ Portuguese ☐ White ☐ Unknown ☐ Other:		
Address: ☐ Same as Proband		Address	City	State Zip Relationship to proband
SPECIMEN INFORMATION* (Please see ambrygen.com/specimen-requirements for details)				
☐ Personal history of allogenic bone marrow or peripheral stem cell transplant		☐ Current diagnosis of heme malignancy, Type:		
Collection Date	Specimen ID		Medical Record #	
*Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. See ambrygen.com/specimen-requirements for details.				
Collection Assistance: ☐ Phlebotomy draw** ☐ Send saliva kit to patient ☐ Send buccal kit to patient ☐ Insurance preverification first (available for ExomeNext® and GenomeNext™) ** As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.				
CLINICAL INFORMATION				
Does the family member have any features similar to the proband? ☐ Yes ☐ No ☐ Partially ☐ Possibly				
Describe:				
SECONDARY FINDINGS				
Secondary findings results are available for each family member sequenced as part of the trio. Check "decline" to opt-out of the ACMG Recommended List of secondary findings. If left unchecked, secondary findings will be reported for this family member.				
☐ Decline				

Clinical Genomics Test Requisition Form - Page 3 of 6

INDICATION(S) FOR TESTING		
ICD-10 code(s):	Will medical management change depending upon the results of the test? ☐ Yes ☐ No	
PROBAND'S PRIMARY INDICATION FOR TESTING		
Please describe in a few words the main reason for ordering exome or genome testing (<i>Please also provide clinic notes and pedigree</i>):		
PROBAND'S CLINICAL OVERVIEW (Check yes for all that apply)		
☐ Yes ☐ No Audiologic/Otolaryngologic ☐ Yes ☐ No Cardiovascular ☐ Yes ☐ No Craniofacial ☐ Yes ☐ No Dental ☐ Yes ☐ No Dysmorphic Features ☐ Yes ☐ No Dermatologic ☐ Yes ☐ No Endocrine ☐ Yes ☐ No Fetal (<i>Please complete and attach the Prenatal Form</i>) ☐ Yes ☐ No Gastrointestinal ☐ Yes ☐ No Genitourinary ☐ Yes ☐ No Growth Disorders: ☐ Yes ☐ No Undergrowth ☐ Yes ☐ No Overgrowth ☐ Yes ☐ No Failure to thrive	☐ Yes ☐ No Hematologic ☐ Yes ☐ No Immunologic/Infectious/Allergy ☐ Yes ☐ No Metabolic/Biochemical ☐ Yes ☐ No Movement Disorder ☐ Yes ☐ No Musculoskeletal/Structural ☐ Yes ☐ No Multiple Congenital Anomalies ☐ Yes ☐ No Neurologic ☐ Yes ☐ No Seizures/Epilepsy ☐ Yes ☐ No Autism Spectrum Disorder ☐ Yes ☐ No Developmental Delay/Intellectual disability ☐ Yes ☐ No Ataxia/Spasticity ☐ Yes ☐ No Psychiatric ☐ Yes ☐ No Abnormal brain MRI ☐ Yes ☐ No Obstetric ☐ Yes ☐ No Oncologic	☐ Yes ☐ No Ophthalmologic ☐ Yes ☐ No Pulmonary ☐ Yes ☐ No Renal ☐ Yes ☐ No Tone abnormalities ☐ Yes ☐ No Hypotonia ☐ Yes ☐ No Hypertonia
ADDITIONAL CLINICAL DETAILS		
Autism: ☐ no autistic behaviors ☐ autistic behaviors (describe): _____ Dysmorphic Features (describe): _____ Congenital Anomalies (describe): _____ History of Seizures ☐ Yes ☐ No ☐ diagnosed epilepsy Seizure type(s): _____ Progressive disease ☐ Yes ☐ No Previous Studies MRI/CT studies (findings): _____ Chromosome analysis: _____ Microarray analysis: _____ Other molecular studies: _____ Growth Indices (current): Head circumference: _____ % Weight: _____ % Height: _____ % Differential diagnosis/Genes of interest: _____ Previously Reported Variants: <i>See instructions for reporting of Previously Reported Variants on the Supplemental Information Page</i> Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____ Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____ Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____		
FAMILY HISTORY (Please attach pedigree)		
Is anyone in the family affected with a similar phenotype as the proband? ☐ NO ☐ YES, please list exact relationship to proband, symptoms and age of onset of symptoms: _____ _____ Is there any consanguinity (conception between blood relatives) in the family? ☐ NO ☐ YES If yes please describe: _____ _____ Known Familial Variant: Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____		

Clinical Genomics Test Requisition Form - Page 4 of 6

Please check the box next to the test(s) being ordered below. If this TRF is sent to Ambry without or ahead of the sample, it will be treated as a preverification. If test ordered is different than the test preverified, we will honor what is on the TRF order form with the sample. Preverification will only be performed for ExomeNext® and GenomeNext™ testing.

For Reflex or Concurrent Testing: See Reflex or Concurrent Testing section of the Supplemental Information page.			
Test 1: _____ ☐ Reflex to _____ ☐ Concurrent with _____		Test 2: _____ ☐ Reflex to _____ ☐ Concurrent with _____	
Test 3: _____ ☐ Reflex to _____ ☐ Concurrent with _____			

Check	Test Name	Test Code	Description
Exome			
! REQUIRED: Select a Primary Test Order			
☐	ExomeNext® ☐ Proband only ☐ Duo ☐ Trio	9900	Exome sequencing
☐	ExomeNext-Rapid®	9999-R	Rapid trio exome sequencing including a defined list of established disease-causing variants in the mitochondrial DNA (mtDNA)
ExomeNext Supplemental Test Options <i>(Primary test order required. See descriptions for details.)</i>			
☐	ACMG Secondary Findings* ☐ Decline	9920	Analysis of genes included in the ACMG Recommended List of secondary findings. Secondary findings results are available free of charge for the proband and each family member who is fully sequenced as part of the duo/trio.
☐	ExomeReveal® RNA Analysis	9990	RNA analysis is available with all ExomeNext orders except for ExomeNext-Rapid. EDTA and PAX-gene RNA tubes are required.
☐	Mito DNA	9900-M	Analysis of a defined list of established disease-causing variants in the mitochondrial DNA (mtDNA)
Genome			
! REQUIRED: Select a Primary Test Order			
☐	GenomeNext™ ☐ Proband only ☐ Duo ☐ Trio	7000	Genome sequencing including sequencing of mitochondrial DNA (mtDNA)
GenomeNext Supplemental Test Options <i>(Primary test order required.)</i>			
☐	ACMG Secondary Findings* ☐ Decline	7002	Analysis of genes included in the ACMG Recommended List of secondary findings. Secondary findings results are available free of charge for the proband and each family member who is fully sequenced as part of the duo/trio.
☐	GenomeReveal™ RNA Analysis	7004	RNA analysis is available with all GenomeNext orders. EDTA and PAX-gene RNA tubes are required. Genome Reveal will be added automatically if a PAX tube is provided.
Fragile X syndrome and Chromosomal Microarray			
☐	Fragile X syndrome	4544	FMR1 repeat expansion analysis and methylation studies
☐	SNP Array	5490	Chromosomal microarray (>2.6 million copy number probes and 750,000 SNP probes)
*Secondary Findings: Check "decline" to opt-out of the ACMG Recommended List of secondary findings. If left unchecked, secondary findings will be reported.			

KNOWN VARIANT ANALYSIS (Please include a copy of relative's report)
 Gene(s): _____ Variant(s) (c. and/or p.): _____
 Relative Name: _____
 Relationship to Relative: _____ Accession # (If tested at Ambry): _____
 Positive control sample: ☐ will be provided ☐ already at Ambry ☐ not available

FOR PRENATAL SPECIMENS, POC OR CORD BLOOD: MATERNAL CELL CONTAMINATION ANALYSIS REQUIRED
 Both test codes required for fetal specimens.
☐ 1260 MCC for amniotic fluid culture or CVS
☐ 1262 MCC Reference for maternal blood sample (No Charge)

OTHER ORDER
 Please visit ambrygen.com/tests for details.
 Test Code: _____ Test Name: _____
 Notes:

ORDERING CHECKLIST (Required*)
☐ Proband specimen
☐ Clinical Genomics TRF with patient & clinician signatures
☐ Clinical history (attach clinic notes)
☐ Medical Necessity Form (insurance orders only) (see page 5)
☐ Copy of Insurance Card (insurance orders only)
Orders with missing requirements will be placed on hold until all requirements are received.

ORDERING CHECKLIST (Highly Recommended)
☐ Family member specimens *Please send all first degree and other informative relatives within 4 weeks of the order.*
☐ Family history or pedigree
☐ Previous test results

CONTACT INFORMATION	
For ExomeNext and GenomeNext™ preverification requests please send the Medical Necessity Form and Clinical Genomics TRF to preverification@ambrygen.com or fax to 949-900-5501.	
All other documents can be secure uploaded at ambrygen.com/secure-upload , or faxed to 949-900-5501.	
AmbryPort is a secure client portal that allows order submission, test status updates, insurance authorization status and report downloads. All required documents can be completed and directly uploaded through AmbryPort during the ordering process or after order submission. Please visit portal.ambrygen.com/signup to sign up.	

Supplemental Information - Page 5 of 6

Electronic ordering is also available via AmbryPort®. Please visit <https://portal.ambrygen.com/login> to log in to the online portal.

Specimen Requirements

Blood/saliva/buccal swab sample from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva/buccal swab sample from patients with active hematological disease is not recommended. An alternative specimen may be needed. See ambrygen.com/specimen-requirements for details.

Fetal specimens, cord blood and POC will have maternal cell contamination studies added for a charge. Maternal and fetal specimen required. Please see page 4 for Maternal Cell Contamination sample submission test codes. Fetal specimens, cord blood, and POC are not accepted sample types for GenomeNext™.

Known variant analysis should be accompanied by a copy of the original testing report or internal Ambry testing information (internal Ambry ID, Name/DOB). Please review information about positive controls and other specifics at ambrygen.com/knownvariantanalysis.

Previously Reported Variants

ExomeNext® or GenomeNext™ report comments about the presence or absence of a variant previously reported **in the patient** require the "Previously Reported Variant" section of this form to be completed accurately, including an internal Ambry reference ID and/or a copy of the positive family member's lab report. Acceptable types of Ambry identifiers include:

- Accession number
- Order number
- Name and date of birth

Previously reported variant requests without an internal Ambry reference ID or positive lab report will not receive a variant-specific report comment.

Variant-specific report comments about the presence or absence of a variant previously reported **in a family member** are not included in ExomeNext®, GenomeNext™, or Neurology panel reports.

Reflex or Concurrent Testing

Concurrent testing is when multiple tests are initiated at the same time. When multiple tests are ordered on the same test requisition form, testing will be run concurrently unless otherwise specified.

Reflex testing is when a subsequent test is initiated pending the outcome of the initial test. Reflex testing may result in delayed reporting of results.

For reflex test orders:

- Any diagnostic finding at any step will result in cancellation of any subsequent reflex tests.
- Non-diagnostic findings (including VUS or Uncertain results) will automatically reflex to the subsequent test.
- Secondary findings results do not impact whether a subsequent test is initiated or canceled.

ExomeNext Medical Necessity Form - Page 6 of 6

REQUIRED FOR INSURANCE ORDERS ONLY (NOT REQUIRED FOR CIGNA MEMBERS)

This form is required if you are ordering Exome testing and wish to have the patient's insurance billed. Please complete and submit with the TRF and a copy of clinical notes. This form replaces the Letter of Medical Necessity.

1. Has the patient had previous Whole Exome Sequencing (WES) performed?

☐ Yes, date performed: _____

☐ No

2. Does this patient have a clinical presentation consistent with the following (select all that apply):

☐ Multiple abnormalities affecting unrelated organ systems (please specify): _____

OR two of the following:

☐ Abnormality affecting a single organ system(specify): _____

☐ Significant intellectual disability, symptoms of a complex neurodevelopmental disorder (i.e. self-injurious behavior, reverse sleep-wake cycle, or seizure/epilepsy), or severe neuropsychiatric condition (e.g. schizophrenia, bipolar, Tourette syndrome)

☐ Family history strongly implicating a genetic etiology (please specify findings and relationships): _____

☐ Period of unexplained developmental regression (unrelated to autism or epilepsy)

3. Are the results of this WES test expected to directly influence this patient's medical management recommendations and clinical outcome?

☐ Yes (please describe): _____

☐ No

4. Please describe the genetic tests that would be indicated if WES were NOT performed (i.e., single gene tests, gene panels, etc.):

☐ Chromosomal microarray

☐ Single gene test(s): _____

☐ Multigene panel(s): _____

☐ Other genetic test(s): _____

5. Please describe follow-up procedures & frequency that would be needed if WES were NOT performed (i.e., lumbar puncture, imaging studies, brain MRI, etc.):

☐ Imaging study: _____

☐ Surgery: _____

☐ Biopsy: _____

☐ Other: _____